IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Trial Details

NCT ID
NCT05039801
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Bevacizumab
  • Glutaminase-1 Inhibitor IACS-6274
  • Paclitaxel
  • Capivasertib
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Provision of written informed consent prior to any study related procedures and compliance with the requirements and restrictions listed in the inf…
  • Male or female patients ≥18 years of age at the time of study entry who agree to participate by giving written informed consent prior to participat…
  • Histologically or cytologically confirmed advanced solid tumors, specifically:
  • Dose Escalation for Part A may include:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →